Cargando…

Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review

Pulmonary sarcomatoid carcinoma (PSC) is an uncommon variant of non-small cell lung cancer (NSCLC), known for its unfavorable prognosis. Previous studies have elucidated that PSC generally exhibits a significant expression of programmed death-ligand 1 (PD-L1), an elevated tumor mutation burden, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Yingmei, Dong, Yi, Yi, Lina, Yang, Guifang, Xiao, Mengxia, Li, Qingqing, Zhao, Chen, Ye, Dafu, Yao, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618617/
https://www.ncbi.nlm.nih.gov/pubmed/37920159
http://dx.doi.org/10.3389/fonc.2023.1241475
_version_ 1785129815971463168
author Wen, Yingmei
Dong, Yi
Yi, Lina
Yang, Guifang
Xiao, Mengxia
Li, Qingqing
Zhao, Chen
Ye, Dafu
Yao, Yi
author_facet Wen, Yingmei
Dong, Yi
Yi, Lina
Yang, Guifang
Xiao, Mengxia
Li, Qingqing
Zhao, Chen
Ye, Dafu
Yao, Yi
author_sort Wen, Yingmei
collection PubMed
description Pulmonary sarcomatoid carcinoma (PSC) is an uncommon variant of non-small cell lung cancer (NSCLC), known for its unfavorable prognosis. Previous studies have elucidated that PSC generally exhibits a significant expression of programmed death-ligand 1 (PD-L1), an elevated tumor mutation burden, and marked vascular invasion. These factors imply the possible effectiveness of treatments like immunotherapy and anti-angiogenic therapy. The subject of this case was a 65-year-old male diagnosed with advanced PSC, characterized by high PD-L1 expression and devoid of known driver gene mutations. Owing to the restrictions imposed by the COVID-19 pandemic, the patient initially underwent home-based treatment with anlotinib, which led to symptomatic improvement after a single treatment cycle. Subsequent hospitalization allowed for the administration of anlotinib plus Pembrolizumab, resulting in a partial response. Radiotherapy was necessitated due to local disease progression. But after 15 cycles of treatment with Pembrolizumab, hyperprogression was observed. The patient’s overall survival spanned 14 months, with no evident adverse reactions to the medications. Genomic analysis revealed potential associations between treatment efficacy and mutations in the TP53, NF1, and MET genes. This case underscores the effectiveness and safety of a first-line treatment regimen combining pan-target anti-angiogenic therapy (anlotinib) with anti-tumor immunotherapy.
format Online
Article
Text
id pubmed-10618617
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106186172023-11-02 Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review Wen, Yingmei Dong, Yi Yi, Lina Yang, Guifang Xiao, Mengxia Li, Qingqing Zhao, Chen Ye, Dafu Yao, Yi Front Oncol Oncology Pulmonary sarcomatoid carcinoma (PSC) is an uncommon variant of non-small cell lung cancer (NSCLC), known for its unfavorable prognosis. Previous studies have elucidated that PSC generally exhibits a significant expression of programmed death-ligand 1 (PD-L1), an elevated tumor mutation burden, and marked vascular invasion. These factors imply the possible effectiveness of treatments like immunotherapy and anti-angiogenic therapy. The subject of this case was a 65-year-old male diagnosed with advanced PSC, characterized by high PD-L1 expression and devoid of known driver gene mutations. Owing to the restrictions imposed by the COVID-19 pandemic, the patient initially underwent home-based treatment with anlotinib, which led to symptomatic improvement after a single treatment cycle. Subsequent hospitalization allowed for the administration of anlotinib plus Pembrolizumab, resulting in a partial response. Radiotherapy was necessitated due to local disease progression. But after 15 cycles of treatment with Pembrolizumab, hyperprogression was observed. The patient’s overall survival spanned 14 months, with no evident adverse reactions to the medications. Genomic analysis revealed potential associations between treatment efficacy and mutations in the TP53, NF1, and MET genes. This case underscores the effectiveness and safety of a first-line treatment regimen combining pan-target anti-angiogenic therapy (anlotinib) with anti-tumor immunotherapy. Frontiers Media S.A. 2023-10-18 /pmc/articles/PMC10618617/ /pubmed/37920159 http://dx.doi.org/10.3389/fonc.2023.1241475 Text en Copyright © 2023 Wen, Dong, Yi, Yang, Xiao, Li, Zhao, Ye and Yao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wen, Yingmei
Dong, Yi
Yi, Lina
Yang, Guifang
Xiao, Mengxia
Li, Qingqing
Zhao, Chen
Ye, Dafu
Yao, Yi
Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
title Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
title_full Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
title_fullStr Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
title_full_unstemmed Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
title_short Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
title_sort anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618617/
https://www.ncbi.nlm.nih.gov/pubmed/37920159
http://dx.doi.org/10.3389/fonc.2023.1241475
work_keys_str_mv AT wenyingmei anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview
AT dongyi anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview
AT yilina anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview
AT yangguifang anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview
AT xiaomengxia anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview
AT liqingqing anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview
AT zhaochen anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview
AT yedafu anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview
AT yaoyi anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview